中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

18 records (took 0.017 seconds)

    Methods for identifying a candidate for treatment of obesity
    11.
    发明授权
    Methods for identifying a candidate for treatment of obesity 有权
    识别肥胖症治疗候选人的方法

    公开(公告)号：US07279282B2

    公开(公告)日：2007-10-09

    申请号：US11177860

    申请日：2005-07-08

    Applicant: Scott Mellis

    Inventor： Scott Mellis

    IPC: C12Q1/68 ,  C12P19/34 ,  A01N37/18 ,  A61K38/00

    CPC classification number: C12Q1/6883 ,  C12Q1/6881 ,  C12Q2600/106 ,  C12Q2600/156

    Abstract: Methods of identifying human subjects for treatment of obesity or an obesity-related condition with ciliary neurotrophic factor (CNTF) or a CNTF-related molecule, such as Axokine®, based on the presence of human leukocyte antigen (HLA) DRβ1 allele 1501 or the absence of HLA DRβ1 allele 0701.

    Abstract translation: 基于人白细胞抗原（HLA）DRbeta1等位基因1501的存在，鉴定用于治疗肥胖或与睫状神经营养因子（CNTF）或CNTF相关分子（例如Axokine）的肥胖相关状况的人类受试者的方法 或不存在HLA DRbeta1等位基因0701。

    Methods of Using IL-1 Antagonists to Treat Autoinflammatory Disease
    16.
    发明申请
    Methods of Using IL-1 Antagonists to Treat Autoinflammatory Disease 审中-公开
    使用IL-1拮抗剂治疗自身炎症性疾病的方法

    公开(公告)号：US20090156492A1

    公开(公告)日：2009-06-18

    申请号：US12259366

    申请日：2008-10-28

    Applicant: Scott Mellis ,  Margaret Karow ,  George D. Yancopoulos ,  Joanne Papadopoulos

    Inventor： Scott Mellis ,  Margaret Karow ,  George D. Yancopoulos ,  Joanne Papadopoulos

    IPC: A61K38/17 ,  A61P29/00

    CPC classification number: C07K14/7155 ,  A61K38/00 ,  A61K38/177 ,  A61K45/06 ,  A61K2300/00

    Abstract: Methods of treating, inhibiting, or ameliorating an autoinflammatory disorder, disease, or condition in a subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the autoinflammatory disorder, disease, or condition is treated, inhibited, or ameliorated. The IL-1 antagonist is an IL-1 trap, preferably comprising a sequence selected from the group consisting of SEQ ID NO: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, or a substantially identical having at least 95% identity to the sequence shown in SEQ ID NO: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and capable of binding and inhibiting IL-1. The therapeutic methods are useful for treating a human adult or child suffering from Neonatal Onset Multisystem Inflammatory Disorder (NOMID/CINCA), Muckle-Wells Syndrome (MWS), Familial Cold Autoinflammatory Syndrome (FCAS), familial mediterranean fever (FMF), or systemic onset juvenile rheumatoid arthritis (Still's Disease).

    Abstract translation: 在有需要的受试者中治疗，抑制或改善自身炎性疾病，疾病或病症的方法，包括向需要治疗的受试者施用治疗量的白细胞介素1（IL-1）拮抗剂，其中所述自身炎性疾病，疾病 ，或条件得到治疗，抑制或改善。 IL-1拮抗剂是IL-1捕获物，优选包含选自SEQ ID NO：4,6,8,10,12,14,16,18,20,22,24,26， 或与SEQ ID NO：4,6,8,10,12,14,16,18,20,22,24,26中所示的序列具有至少95％的同一性，并能够结合和抑制IL- 1。 治疗方法可用于治疗患有新生儿起始多系统炎症性疾病（NOMID / CINCA），Muckle-Wells综合征（MWS），家族性冷自身炎症综合征（FCAS），家族性地中海热（FMF）或全身性 发病青少年类风湿关节炎（Still氏病）。

    Use of IL-1 antagonists to treat gout and pseudogout
    18.
    发明申请
    Use of IL-1 antagonists to treat gout and pseudogout 审中-公开
    使用IL-1拮抗剂治疗痛风和假眼

    公开(公告)号：US20080300185A1

    公开(公告)日：2008-12-04

    申请号：US11975593

    申请日：2007-10-19

    Applicant: Catherine Vicary ,  Scott Mellis

    Inventor： Catherine Vicary ,  Scott Mellis

    IPC: A61K38/17

    CPC classification number: A61K31/165 ,  A61K38/177 ,  A61K38/1793 ,  A61K45/06 ,  A61K2300/00

    Abstract: Methods of treating, inhibiting, or ameliorating gout, including chronic acute (refractory) gout or pseudogout in a human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein gout or pseudogout are inhibited or ameliorated. Preferably, the IL-1 antagonist is the protein of SEQ ID NO:10 (rilonacept).

    Abstract translation: 包括对有需要的人类受试者的痛风，包括慢性急性（难治性）痛风或假阴性的治疗，抑制或改善疼痛的方法，包括向需要治疗的受试者施用治疗量的白细胞介素1（IL-1）拮抗剂，其中痛风 或伪距离被抑制或改善。 优选地，IL-1拮抗剂是SEQ ID NO：10（rilonacept）的蛋白质。

Patent Agency Ranking